stavudine, efavirenz, lamivudine — Competitive Intelligence Brief

stavudine, efavirenz, lamivudine (stavudine, efavirenz, lamivudine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination therapy (NRTI/NNRTI). Area: Infectious Disease / Virology.

phase 3 Antiretroviral combination therapy (NRTI/NNRTI) HIV reverse transcriptase Infectious Disease / Virology Small molecule

Target snapshot

stavudine, efavirenz, lamivudine (stavudine, efavirenz, lamivudine) — Bristol-Myers Squibb. This is a fixed-dose combination of three nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks HIV replication by inhibiting reverse transcriptase.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
stavudine, efavirenz, lamivudine TARGET	stavudine, efavirenz, lamivudine	Bristol-Myers Squibb	phase 3	Antiretroviral combination therapy (NRTI/NNRTI)	HIV reverse transcriptase
Biktarvy Tab	Biktarvy Tab	Southampton Healthcare, Inc.	marketed	Antiretroviral combination therapy (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase, CCR5 co-receptor
Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill	Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill	Charlotte-Paige Rolle, MD	marketed	Antiretroviral combination (integrase inhibitor + nucleoside reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
Raltegravir; Abacavir/Lamivudine	Raltegravir; Abacavir/Lamivudine	Central Institute of Epidemiology, Moscow, Russia	marketed	Antiretroviral combination therapy (integrase inhibitor + nucleoside reverse transcriptase inhibitors)	HIV integrase; HIV reverse transcriptase
Raltegravir and Abacavir/Lamivudine	Raltegravir and Abacavir/Lamivudine	Denver Infectious Disease Consultants, PLLC	marketed	Antiretroviral combination (INSTI + NRTI)	HIV integrase, HIV reverse transcriptase
Raltegravir and truvada	Raltegravir and truvada	The University of Texas Health Science Center, Houston	marketed	Antiretroviral combination (INSTI + NRTI)	HIV integrase; HIV reverse transcriptase
Rilpivirine + darunavir/cobicistat	Rilpivirine + darunavir/cobicistat	A.O. Ospedale Papa Giovanni XXIII	marketed	Antiretroviral combination (NNRTI + protease inhibitor + pharmacokinetic booster)	HIV reverse transcriptase, HIV protease

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination therapy (NRTI/NNRTI) class)

1. Azienda Ospedaliera San Gerardo di Monza · 1 drug in this class
2. Bristol-Myers Squibb · 1 drug in this class